⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28292936 | 0.69 | — | — | |
| Lesogaberan SCHEMBL349233 | 0.69 | — | — | |
| Lesogaberan SCHEMBL349234 | 0.69 | — | — | |
| Lesogaberan SCHEMBL348931 | 0.69 | — | — | |
| SCHEMBL5594238 | 0.68 | — | — | |
| SCHEMBL10485819 | 0.65 | — | — | |
| SCHEMBL1888584 | 0.63 | — | — | |
| SCHEMBL3439120 | 0.63 | — | — | |
| SCHEMBL349589 | 0.63 | — | — | |
| SCHEMBL3439121 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621282-A2 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | The Regents of the University of California (US) | 2013-08-07 | — | — | EP | claimed |
| WO-2012050907-A2 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-04-19 | — | — | WO | claimed |
| JP-3914435-B2 | — | — | 2007-05-16 | — | — | JP | claimed |
| JP-2003516407-A | — | — | 2003-05-13 | — | — | JP | claimed |
| EP-1240172-A1 | NEW AMINOPROPYLPHOSPHINIC ACIDS | AstraZeneca AB (SE) | 2002-09-18 | — | — | EP | claimed |
| WO-2001042252-A1 | NEW AMINOPROPYLPHOSPHINIC ACIDS | ASTRAZENECA AB (SE) | 2001-06-14 | — | — | WO | claimed |
| US-11872200-B2 | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-16 | — | — | US | disclosed |
| EP-2621282-A2 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | The Regents of the University of California (US) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012050907-A2 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-04-19 | — | — | WO | disclosed |
| WO-2006071186-A1 | USE OF GABAB RECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
| WO-2004000856-A1 | COMBINATION OF A REFLUX INHIBITOR AND AN IMIDAZOPYRIDINE FOR THE TREATMENT OF GERD | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | disclosed |
| EP-1240172-A1 | NEW AMINOPROPYLPHOSPHINIC ACIDS | AstraZeneca AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001042252-A1 | NEW AMINOPROPYLPHOSPHINIC ACIDS | ASTRAZENECA AB (SE) | 2001-06-14 | — | — | WO | disclosed |